MCMedicalCodingSoftware
Free trial
XU7G71B

XU7G71B: Dilation of Vagina with Temporary Electromechanical Intraluminal Device, Via Natural or Artificial Opening, New Technology Group 11

Billable / specific codeICD-10-PCS

CMS abbreviated title: Dilate Vagina w Tmp Electr Intrlum, Via Opening, New Tech 11

How XU7G71B is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology: What family of procedure this is
  2. UBody systemWhich system it acts on
  3. 7Root operationThe objective: the verb of the procedure
  4. GBody partThe specific site
  5. 7ApproachHow the site was reached
  6. 1DeviceWhat was left in place, if anything
  7. BQualifierA further distinction where one applies

Codes near XU7G71B

In CMS’s own ordering, which groups codes that differ by only the last character or two, usually the approach, device or qualifier.

  • XRRG0L8Replacement of Right Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8
  • XRRG0M8Replacement of Right Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8
  • XRRH0L8Replacement of Left Knee Joint with Synthetic Substitute, Lateral Meniscus, Open Approach, New Technology Group 8
  • XRRH0M8Replacement of Left Knee Joint with Synthetic Substitute, Medial Meniscus, Open Approach, New Technology Group 8
  • XT25XE5Monitoring of Kidney using Fluorescent Pyrazine, External Approach, New Technology Group 5
  • XU7G71BDilation of Vagina with Temporary Electromechanical Intraluminal Device, Via Natural or Artificial Opening, New Technology Group 11
  • XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW01329Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9
  • XW01348Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
  • XW0134CIntroduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12
  • XW0136AIntroduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10
  • XW013F5Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
  • XW013G6Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6
ICD-10-PCSFY2027